Read by QxMD icon Read

Endocrine Practice

Yavuz Çağır, Mustafa Altay, Büşra Betül Çağır, Erman Çakal, Tolga Akkan, Canan Yıldız, Yasemin Ünsal, Murat Dağdeviren, Esin Beyan
Purpose Non-Functioning Pituitary Adenoma (NFPA) accounts for 30% of all pituitary adenomas and its incidence has been increasing compared to previous years. Increased risk of cardiovascular effects shown in recent studies is noteworthy in patients with NFPA diagnosis and the number of studies on the subject is limited. In this study, we aim to assess possible cardiovascular effects and risk via arterial stiffness measurements in patients diagnosed with NFPA. Methods We performed arterial stiffness measurements for 30 patients diagnosed with NFPA and 30 healthy volunteers and compared the results to explore the relationship between arterial stiffness parameters, hormone levels and adenoma size...
July 5, 2018: Endocrine Practice
Amar Agha, Lucy Ann Behan, Hannah Forde, Kathy Maher, Norman F Taylor, Diarmuid Smith, Christopher J Thompson, William M Drake, John P Monson
Purpose Pituitary patients with different aetiologies of hypopituitarism exhibit differing phenotypes despite similar replacement therapy strategies. We hypothesised that differential regulation of the isoenzyme 11β-hydroxysteroid dehydrogenase 1 (11β-HSD 1), which mediates the net autocrine conversion of cortisone to cortisol in adipose tissues and liver may play a role. Methods We studied 11β-HSD 1 activity (using urine cortisol/cortisone metabolites ratio), in 36 hypopituitary patients with treated craniopharyngiomas, treated remitted Cushing's disease and treated non-functioning pituitary adenomas+prolactinomas on and off GH (growth hormone) replacement...
July 5, 2018: Endocrine Practice
Xiuhua Shen, Jianfang Cai, Jingsheng Gao, Anand Vaidya, Xuemei Liu, Wen Li, Shuohua Chen, Yong Zhou, Yinge Li, Yanmin Zhang, Jianqiu Zhao, Frank B Hu, Shouling Wu, Xiang Gao
OBJECTIVE: We aimed to investigate whether individuals with severer liver steatosis had a higher risk of developing diabetes in a large cohort study. RESEARCH DESIGN AND METHODS: We prospectively examined the association in 41650 Chinese adults with negative hepatitis-B surface antigen and free of alcohol consumption, diabetes and liver cirrhosis at the baseline. Cox proportional models were used to estimate the risk of diabetes after average 3.6 years follow up...
July 5, 2018: Endocrine Practice
Jennifer G Foster, Sarah K Wood, Marc A Pfeffer, David L DeMets, Alan Garber, Charles H Hennekens
No abstract text is available yet for this article.
July 5, 2018: Endocrine Practice
Roh-Eul Yoo, Ji-Hoon Kim, Eun-Hee Jang, Sang Won Jo, Koung Mi Kang, Tae Jin Yun, Seung Hong Choi, Chul-Ho Sohn, Sung-Hye You, Hye Jeong Choi, Soo Chin Kim, Jung Hyo Rhim, Sun-Won Park
OBJECTIVE: To explore a comprehensive approach for on-site gross visual assessments of liquid-based cytology (LBC) specimens of thyroid nodules and to determine morphologic criteria that help predict non-diagnostic rates. METHODS: Two hundred nodules from 165 patients, who underwent FNA at our hospital, were included in this prospectively designed, retrospective analysis. Specimens were visually assessed on-site for three morphologic categories (specimen color, specimen volume, and particle count) using a 5-point grading...
July 5, 2018: Endocrine Practice
Morgan C Gettle, Joshua M Tate, Mark W True
No abstract text is available yet for this article.
July 5, 2018: Endocrine Practice
Lee Kallenbach, Amy M Shui, Wendy Y Cheng, Tao Fan, Wenli Hu, Miriam L Zichlin, Mei Sheng Duh, Fen Ye, Philip A Levin
OBJECTIVE: To understand factors associated with intensification of basal insulin therapy and treatment impact on clinical outcomes in patients with type 2 diabetes (T2D). METHODS: In this retrospective, observational study of the Practice Fusion electronic health record database, eligible patients were adults with T2D, ≥1 basal insulin prescription and office visit in the 6 months before an A1C test >7.0% (index date), and no other injectable prescriptions in the 12 months before index date...
July 5, 2018: Endocrine Practice
Aisha Sheikh, Minaz Mawani, Saeed Ahmed Mahar
OBJECTIVES: Ramadan is the ninth month in the lunar calendar during which Muslims fast from predawn to sunset and major changes occur in their dietary, sleep and physical activity patterns. Most patients with hypothyroidism are unable to comply with the proper timings of Levo-thyroxine (LT4) administration. The objective of the study is to determine the change in thyroid stimulating hormone (TSH) level and quality of life (QOL) before and after Ramadan in patients with primary hypothyroidism...
July 5, 2018: Endocrine Practice
Max Gill, Harmeet Chhabra, Mona Shah, Cyrus Zhu, George Grunberger
OBJECTIVE: To study the impact of the C-peptide and β-cell autoantibody testing required by the Center for Medicare and Medicaid Services (CMS) on costs/utilization for patients with diabetes mellitus (DM) initiating continuous subcutaneous insulin infusion (CSII) therapy. METHODS: This retrospective study used propensity score-matched patients. Analysis 1 compared patients 1-year pre- and 2-year post-CSII adoption who met or did not meet CMS criteria. Analysis 2 compared Medicare Advantage patients using CSII or multiple daily injections (MDI), who did not meet CMS criteria, for 1-year pre- and 1-year post-CSII adoption...
May 31, 2018: Endocrine Practice
Jason R Bisson, Kelly J Chan, Joshua D Safer
CONTEXT: Existing transgender treatment guidelines suggest that for transfeminine hormone treatment there is a need to monitor prolactin levels. Also, recent studies suggest that use of cyproterone acetate as an adjunctive anti-androgen during transgender hormone treatment may elevate serum prolactin. OBJECTIVE: We sought to determine whether the reported relationship between transfeminine estradiol treatment and hyperprolactinemia would be evident when the regimen used spironolactone as the adjunctive anti-androgen...
April 30, 2018: Endocrine Practice
Z Ismadi, A J Caswell, H A Tran
No abstract text is available yet for this article.
April 24, 2018: Endocrine Practice
Suleiman Mustafa-Kutana
No abstract text is available yet for this article.
April 24, 2018: Endocrine Practice
Edy Kornelius, Yi-Sun Yang, Chien-Ning Huang, Yu-Hsun Wang, Shih-Chang Lo, Yung-Rung Lai, Jeng-Yuan Chiou
OBJECTIVE: Over the past three decades, few studies on hyperthyroidism treatment trends have been reported. Therefore, we used a nationwide population-based database to evaluate the current practices and management of hyperthyroidism in Taiwan. METHODS: This retrospective study included a random selection of 1 million people in Taiwan between 2004 and 2010. Hyperthyroidism patients who received anti-thyroid drugs (ATD), radioactive iodine (RAI), or surgery were identified...
April 24, 2018: Endocrine Practice
R Mack Harrell, Stephanie A Eyerly-Webb, Nat E Pinnar, Allan C Golding, Courtney M Edwards, David N Bimston
OBJECTIVE: Afirma Gene Expression Classifier® (Afirma GEC® ) molecular analysis (Veracyte, Inc.; San Francisco, CA) is a negative predictive value (NPV) test developed to reduce the number of thyroidectomies in thyroid nodule patients with indeterminate cytology. GEC technology has reportedly reduced unnecessary thyroid surgery, but few studies have examined Afirma GEC false negative rates since usually patients with GEC benign nodules do not undergo surgery for definitive diagnosis...
April 24, 2018: Endocrine Practice
Carmen Polanco Santos, Zahrae Sandouk, Divya Yogi-Morren, Richard Prayson, Pablo Recinos, Laurence Kennedy, Amir H Hamrahian, Kevin M Pantalone
OBJECTIVE: To characterize a single referral center experience with thyroid-stimulating hormone (TSH)-staining adenomas. METHODS: A retrospective chart review was conducted on histopathologic-proven TSH-staining adenomas resected between 2000-2015 at a single center. Tumors were classified as functional (hormonally active) or silent (hormonally inactive). Categorical variables were summarized using counts (n) and percentages; continuous variables were summarized using medians and ranges...
June 2018: Endocrine Practice
Adriana Ioachimescu
No abstract text is available yet for this article.
June 2018: Endocrine Practice
Roma Y Gianchandani, Francisco J Pasquel, Daniel J Rubin, Kathleen M Dungan, Priyathama Vellanki, Heqiong Wang, Isabel Anzola, Patricia Gomez, Israel Hodish, Sangeeta Lathkar-Pradhan, Jennifer Iyengar, Guillermo E Umpierrez
OBJECTIVE: Few randomized controlled trials have focused on the optimal management of patients with type 2 diabetes (T2D) during the transition from the inpatient to outpatient setting. This multicenter open-label study explored a discharge strategy based on admission hemoglobin A1c (HbA1c) to guide therapy in general medicine and surgery patients with T2D. METHODS: Patients with HbA1c ≤7% (53 mmol/mol) were discharged on sitagliptin and metformin; patients with HbA1c between 7 and 9% (53-75 mmol/mol) and those >9% (75 mmol/mol) were discharged on sitagliptinmetformin with glargine U-100 at 50% or 80% of the hospital daily dose...
June 2018: Endocrine Practice
Aaroh M Parikh, James W Suliburk, Fanny E Morón
OBJECTIVE: ( 1) Review the anatomy and epidemiology of ectopic parathyroid adenomas (EPAs), ( 2) summarize the role of relevant imaging modalities in the localization of EPAs, and ( 3) characterize surgical approaches for various ectopic locations. METHODS: Literature review of published English-language articles from 1995 through August 2017. RESULTS: Summary of the literature indicates that the prevalence of EPA is approximately 20% in unexplored patients with primary hyperparathyroidism, but it is as high as 66% in re-operative patients...
June 2018: Endocrine Practice
Gary W Edelson
No abstract text is available yet for this article.
June 2018: Endocrine Practice
Mehrnaz Imani, Mohammad Ebrahim Khamseh, Poopak Asadi, Mohammad Ghorbani, Hamideh Akbari, Fariba Alaei-Shahmiri, Maryam Honardoost, Mahmoud Reza Kaynama, Mojtaba Malek
OBJECTIVE: The present study aimed to evaluate the efficacy of add-on therapy of cabergoline versus raloxifene to long-acting somatostatin analogues (SAs) in patients with inadequately controlled acromegaly. METHODS: This was a prospective, randomized open label clinical trial. Forty-four patients (22 per group) completed the study; where participants received either cabergoline (3 mg/week) or raloxifene (60 mg twice daily) add-on therapy for 12 weeks in a parallel manner...
June 2018: Endocrine Practice
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"